S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
NASDAQ:KMDA

Kamada (KMDA) Stock Forecast, Price & News

$5.28
+0.01 (+0.19%)
(As of 09/20/2023 ET)
Compare
Today's Range
$5.22
$5.32
50-Day Range
$4.86
$5.83
52-Week Range
$3.72
$5.85
Volume
12,515 shs
Average Volume
32,669 shs
Market Capitalization
$236.65 million
P/E Ratio
66.01
Dividend Yield
N/A
Price Target
$11.00

Kamada MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
108.3% Upside
$11.00 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
250.00%
From $0.06 to $0.21 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

39th out of 962 stocks

Pharmaceutical Preparations Industry

11th out of 448 stocks


KMDA stock logo

About Kamada (NASDAQ:KMDA) Stock

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Price History

KMDA Stock News Headlines

Short Interest in Kamada Ltd. (NASDAQ:KMDA) Declines By 68.6%
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Kamada: Q2 Earnings Snapshot
Kamada earnings preview: what to expect
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Kamada: Q1 Earnings Insights
Kamada: Q1 Earnings Snapshot
Here's what Wall Street expects from Kamada's earnings
Kamada Q1 2023 Earnings Preview
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Company Calendar

Last Earnings
8/16/2023
Today
9/21/2023
Next Earnings (Estimated)
11/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMDA
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+108.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,320,000.00
Pretax Margin
2.43%

Debt

Sales & Book Value

Annual Sales
$129.34 million
Cash Flow
$0.03 per share
Book Value
$3.93 per share

Miscellaneous

Free Float
28,640,000
Market Cap
$236.65 million
Optionable
Not Optionable
Beta
0.94
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Amir London (Age 54)
    Chief Exec. Officer
    Comp: $619k
  • Mr. Chaime Orlev (Age 53)
    Chief Financial Officer
    Comp: $396k
  • Mr. Eran Nir (Age 50)
    Chief Operating Officer
    Comp: $371k
  • Mr. Boris Gorelik (Age 42)
    VP of Bus. Devel. & Strategic Programs
    Comp: $337k
  • Mr. David Tsur (Age 73)
    Co-Founder & Deputy Chairman
  • Mr. Nir Livneh B.A. (Age 44)
    L.L.B., VP, Gen. Counsel & Corp. Sec.
  • Ms. Hanni Neheman (Age 53)
    VP of Marketing & Sales
  • Ms. Liron Reshef (Age 52)
    VP of HR
  • Mr. Jon R. Knight
    VP of US Commercial Operations
  • Ms. Shavit Beladev
    VP of Kamada Plasma













KMDA Stock - Frequently Asked Questions

Should I buy or sell Kamada stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings
or view top-rated stocks.

What is Kamada's stock price forecast for 2023?

1 analysts have issued 1-year target prices for Kamada's shares. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price.
View analysts price targets for KMDA
or view top-rated stocks among Wall Street analysts.

How have KMDA shares performed in 2023?

Kamada's stock was trading at $4.01 on January 1st, 2023. Since then, KMDA shares have increased by 31.7% and is now trading at $5.28.
View the best growth stocks for 2023 here
.

Are investors shorting Kamada?

Kamada saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 13,300 shares, a drop of 68.6% from the August 15th total of 42,300 shares. Based on an average daily trading volume, of 27,900 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the company's shares are short sold.
View Kamada's Short Interest
.

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our KMDA earnings forecast
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its earnings results on Wednesday, August, 16th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to the consensus estimate of $34.18 million. Kamada had a trailing twelve-month return on equity of 7.42% and a net margin of 2.35%. During the same period last year, the company earned $0.07 EPS.

What guidance has Kamada issued on next quarter's earnings?

Kamada updated its FY 2023 earnings guidance on Wednesday, August, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.94%), Wells Fargo & Company MN (1.44%), Acadian Asset Management LLC (1.26%), Altshuler Shaham Ltd (0.67%), Bank of Montreal Can (0.11%) and Calton & Associates Inc. (0.04%).

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.28.

How much money does Kamada make?

Kamada (NASDAQ:KMDA) has a market capitalization of $236.65 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does Kamada have?

The company employs 380 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.

This page (NASDAQ:KMDA) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -